Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 10:18:29 AM Tue, 11 May 2021   Contact Information Gabriel Lopez-Berestein, MD Associated Profiles  John Q. Gaines Foundation Professorship for Cancer Research, Professor, Cancer Biology and Experimental Therapeutics, UT MD Anderson Cancer Center, Professor, Biomedical Sciences, Pharmacology and NanoMedicine, UT Health, Adjunct Professor, Bioengineering, Rice Univ, Adjunct Professor, Surgery, Univ of Puerto Rico School of Medicine   MDA 3SCR3.3424, Room No.: Unit 1950    glopez@mdanderson.org     713-792-8140    Faculty Profile    Lab Webpage    Ovarian Neoplasms, Liposomes, Neoplasms, Amphotericin B, Small Interfering RNA, Therapeutics, Growth, MicroRNAs    Associated Profiles Research and Expertise Affiliations Appointments  Research and Expertise Research Interests   My two major areas of interest are, nanoparticulate carriers for the delivery of nucleotides and small molecules in the treatment of cancer, and cell differentiation and apoptosis signaling in cancer. My laboratory exploited the use of lipid based carriers for the delivery of antifungal and anticancer agents, more recently we focused on the development of nanoliposomes and nanoparticles for the delivery of antisense oligonucleotides and siRNA to target major signaling pathways in cancer. Several of these targets were identified to play a prominent role in cell growth in our laboratotry. We established and characterized the mechanisms involved in the suppression of tumor growth both in vitro and in experimental models. We were able to bring from concept to clinic seven different antimicrobial and antitumor agents, of which one, Abelcet, reached the market and others are different stages of clinical development. As part of interest in cell death and differentiation in cancer we characterized the role of non-coding RNA's (and RNA) both as tumor suppressors and oncogenic potential. These findings led to the identification of several proteins involved in key regulatory pathways of cell growth in solid and terms. A present two clinical trials are underway leukemia and another in solid tumors are based on our basic and applied science knowledge in nucleotide therapy.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia John S. Dunn GCC for Chemical Genomics GCC Cluster NanoX  Appointments Title Department / School Institution Professor Cancer Biology and Experimental Therapeutics MD Anderson Cancer Center John Q. Gaines Foundation Professorship Cancer Research MD Anderson Cancer Center

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.